Journal of Commercial Biotechnology

I’ve recently joined the Journal of Commercial Biotechnology as managing editor. Drop me a line if you would like to make a submission.

The most recent issue, edited by Neil Henderson, has just been published:

Volume 13, Issue 3

  • When should you fire the founder?
  • William Bains

  • Constructing a processual model of communication in new product development from a multiple case study of biotechnology SMEs
  • Jennifer Frahm, David C Ireland and Damian Hine

  • A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
  • Gareth Williams

  • Measuring performance of field-medical programmes: Medical science liaison metrics consensus
  • Jane Chin

  • The commercialisation of bioinformatics and the threat of open-source software
  • Joseph F Greco

  • Intellectual property issues in nanotechnology
  • Lars Genieser and Michael Gollin

  • Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost?
  • Pedro Reinares Lara and Emma Gutierrez de Mesa

  • Changing hopes and concerns about gene therapy in Japan
  • Darryl Macer, Yoshihiro Okada, Makoto Nakagawa, MaryAnn Chen Ng and Masakazu Inaba

  • Legal and Regulatory Update
  • ReedSmith

The Journal of Commercial Biotechnology is online at http://www.palgrave-journals.com/jcb. If purchasing a subscription, please use subscriber code NH0707G01.

Twitter Digg Delicious Stumbleupon Technorati Facebook

2 Responses to “Journal of Commercial Biotechnology”

  1. Friedman,
    Well, congratulations and all the best. You’re a hardworking man…there’s no doubt about that.